Progress in clinical study on Ibrutinib in the treatment of Waldenstrom's macroglobulinemia

Waldenstrom macroglobulinemia (WM) is an inert B-cell lymphoma. The main features of the disease are the synthesis and secretion of large amounts of monoclonal IgM and lymphoid plasma cells observed in bone marrow examination. According to statistics analysis, approximately 90%~100% of WM patients have mutation of an important molecular marker: MYD88L265P mutation. Detection of this mutation helps to identify WM and marginal lymphoma. The essence of the disease is a malignant tumor of B cells with variable plasma cell-like differentiation, low incidence, and highly heterogeneous clinical manifestations, which may cause missed diagnosis and misdiagnosis. This article reviews the clinical research progress of the new drug, Ibrutinib, in the treatment of Waldenstrom's macroglobulinemia. Key words: Waldenstrom's macroglobulinemia; Ibrutinib; Bendamustine